---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036940"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:40:50.619208+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech Q2 net loss narrows to $8.3M; FDA aligned on Phase 3 trial for Versamune HPV in HNSCC

## Summary
- Net loss $8.3M ($0.23/share) vs $11.5M ($0.37/share) YoY; R&D expenses down 44% to $4.5M.
- Cash and equivalents $57.7M as of June 30, 2024.
- FDA alignment achieved on Phase 3 VERSATILE-003 trial design for Versamune HPV + pembrolizumab; start Q4 2024.
- Updated VERSATILE-002 data shows median OS of 30 months; abstracts accepted at ESMO, ASTRO, ICIS 2024.
- Total operating expenses reduced to $8.7M from $12.7M YoY.

## SEC filing metadata
- accession: 0001140361-24-036940
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036124036940/0001140361-24-036940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036124036940/ef20034030_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036940
- JSON: https://secwatch.observer/filing/0001140361-24-036940.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.